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Characterization of Xp21 distal to Duchenne muscu- 
lar dystrophy (DMD) in the region containing the genes 
for adrenal hypoplasia congenita (AHC) and glycerol 
kinase deficiency (GKD) has been limited due to a pau- 
city of probes. Two probes were localized between 
DXS28 (C7) and AHC, the yeast artificial chromosome 
insert YHX39 (DXS727) and the polymorphic phage 
clone QST59 (DXS319). A genomic clone, FTl 
(DXS726), 3’ to DMD, was also characterized. Portions 
of the three probes were sequenced and primer pairs 
were generated to amplify a sequence-tagged site 
within each probe. Amplification of DNA from patients 
confirmed the deletion results obtained by Southern 
blot analysis, and these three sequence-tagged sites 
were successfully combined for triplex PCR. In addi- 
tion to facilitating molecular genetic diagnosis in 
Xp21, these probes can be used to identify additional 
YACs and other probes to further increase the genomic 
information and diagnostic capabilities in this 
region. 0 1992 Academic Press, Inc. 
INTRODUCTION 
Analyses of DNA from patients with Xp21 contiguous 
gene syndromes have allowed us to order (Xpter-ten) 
the following loci: adrenal hypoplasia congenita (AHC), 
glycerol kinase (GK), and Duchenne muscular dys- 
trophy (DMD) (reviewed in McCabe, 1989). Character- 
ization of Xp21 distal to DMD has been limited due to a 
paucity of probes. 
This project was initiated to improve the mapping in- 
formation and to develop “sequence-tagged sites” 
(STSs) (Olson et al., 1989) for the Xp21 region distal to 
DMD. Experience with DMD has established the diag- 
nostic value of this information, particularly through 
multiplexing of individual polymerase chain reaction 
(PCR) amplifications (Chamberlain et al., 1988). Ex- 
tending these molecular genetic diagnostic capabilities 
has considerable clinical importance because of the risk 
of death due to Addisonian crisis (Kohlschiitter et al., 
1987) among patients with untreated AHC. We report 
the localization of three probes to this region and the 
acquisition of sequence information from each. Genera- 
tion of individual PCR amplifications and a triplex reac- 
tion has improved mapping and diagnosis in Xp21 distal 
to DMD. 
MATERIALS AND METHODS 
Patients. A chart indicating the phenotypes of the patients and a 
summary of the extent of their deletions is shown in Fig. 1. The pheno- 
type designations adapted for microdeletions in this region will be 
used (McCabe, 1989). These designations describe the known extent 
of the deletion using the initial one or two letters of the deleted loci, 
arranged Xpter to centromere: AGD refers to patients with AHC, 
GKD, and DMD, and AGK refers to AHC and GKD. 
Patients MMC, ESP, GS, JS, JR, MC, MK, CM, and YB have been 
described previously. MMC, ESP, GS, JS, and MC were described 
with AGD (Towbin et al., 1989). JR was diagnosed with AGD and also 
has ophthalmologic features of Oregon eye disease (formerly Aland 
Island eye disease, Pillers et al., 1990; renamed at HGM 11, Davies et 
al., 1991). MK was diagnosed with AGD (Francke et al., 1987; Kohls- 
chiitter, 1987). CM was reported with AGD (Francke etal., 1987; Tow- 
bin et al., 1989; McCabe et al., 1989). YB was diagnosed with AGK 
(Francke et al., 1987; Marlhens et al., 1987). 
TSV has the phenotype of AGD (J. E. Fox). He is developmentally 
delayed and microcephalic with cryptorchidism, hypotonia, failure to 
thrive, and cortical atrophy by CT scan. Laboratory studies revealed 
cortisol levels unresponsive to ACTH stimulation, elevated creatine 
phosphokinase (CPK), and glyceroluria. A lymphocyte karyotype was 
reported to show an interstitial deletion of Xp21: 46,Y,del(X)(p11.4) 
(~22.1). This deletion was also detected in the patient’s mother, but 
not in his maternal grandmother. This patient is being maintained on 
prednisone, Florinef, and a 3-g sodium diet. 
CC has AGD, with adrenal insufficiency, elevated CPK, and glycer- 
oluria (W. K. Seltzer and K. P. Corley). He is treated with cortisol and 
Florinef. To our knowledge CC is unrelated to MC. 
TJ has the AGD phenotype (N. Sakuragawa). At 17 days of age he 
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was diagnosed with congenital adrenal hyperplasia and had a high 
circulating CPK. At 11 months, TJ was diagnosed with complex GKD 
when he presented with acute encephalopathy after a high fever and a 
generalized tonic/clonic seizure. He had DMD by muscle biopsy and 
glyceroluria. CT showed ventricular dilatation and cortical atrophy. 
IY is a male with AGD (S. Yamaguchi). Generalized pigmentation 
was noted shortly after birth. At 22 days of age he was hospitalized for 
failure to thrive, with hypotonia, vomiting, hyponatremia, hyperkale- 
mia, elevated CPK, and glyceroluria (Yasuda et al.. 1990). 
LB108 is a 16.year-old male with the AGD phenotype and a large 
deletion of band Xp21 (G. Romeo). Hypoglycemic crises started at 1 
year of age, and he has prominent glyceroluria. He has been wheel- 
chair-bound from the age of 10, is mentally retarded, and remains 
prepubertal. 
TM has AGD, developmental delay, progressive motor weakness, 
and adrenal insufficiency (W. B. Rizzo). As an infant he had failure to 
thrive, poor feeding, emesis, and diarrhea, and he was “floppy.” At 62 
years of age he presented in adrenal insufficiency crisis, with Addison- 
ian pigmentation and markedly elevated ACTH. He was unresponsive 
to ACTH stimulation and had elevated circulating CPK and glycero- 
luria. Muscle biopsy was consistent with DMD. A lymphocyte karyo- 
type showed no detectable deletion. 
RR has AGK and was referred with the diagnosis of adrenal insuffi- 
ciency and glyceroluria (P. Brosnan). 
DW has isolated AHC (E. R. B. McCabe and G. E. Herman). At 11 
months of age he was developmentally delayed, with increased deep 
tendon reflexes and normal chromosome analysis, serum triglycer- 
ides, CPK, and urinary glycerol. An esotropia was noted at 15 months. 
Previous diagnoses had included primary aldosterone deficiency with 
cortisone deficiency and congenital adrenal hyperplasia. 
TP is a 2:-year-old with isolated AHC (L. G. Biesecker). Chromo- 
some studies, CPK, and urine glycerol were normal. He has been 
treated with NaCl, glucocorticoids, and mineralocorticoids for AHC 
since approximately 3 weeks of age. At 2; years of age he was normal 
developmentally but below the fifth percentile for weight. 
SF was diagnosed with isolated AHC (S. L. Blethen). He has adre- 
nal insufficiency, initially reported to be salt losing only, and is hyper- 
tonic. Since 9 months of age he has been treated with both glucocorti- 
coids and mineralocorticoids. SF has normal CPK, normal serum tri- 
glycerides, normal development, and no glyceroluria. SF has a 
maternal male first cousin who presented in the immediate neonatal 
period with complete adrenal insufficiency. 
Markers. Of the previously described probes (Fig. l), C7 is the 
most centromeric among Ll-4 (DXS68). B24 (DXS67), and C7 
(DXS28) (Towbin et al., 1990). The order of Ll-4 and B24 has been 
established using fluorescence in situ hybridization (Trask et al., 
1992) and through yeast artificial chromosome (YAC) contigs 
(Walker et al., 1991). 
YHX39 was isolated from a YAC library made from a human-ham- 
ster somatic cell hybrid in which the only human DNA was the X 
chromosome and regionally mapped to Xpter + Xp21.2 (Nelson et al., 
1991). A&vector PCR products were sequenced (Nelson et al., 1991), 
and primers were generated. The YHX39R primers are 91-92 
ATGGTTCAAGCATTTTAGAATACTGC and 91-93 GGTCGTTA- 
AAGGTAAGATCCATGTATGGTTC. This YHX39R primer pair 
amplifies a 98.bp fragment, DXS727. 
The plasmid pQST59M4(b) was derived from the Ch35 clone 
QST59, which was isolated from the DOE phage library 
(LAOXNLOl) as described (Die&Band et al., 1990). Restriction frag- 
ments from pQST59 were subcloned and portions of these clones were 
sequenced. A unique sequence was found in a Tth 1111-XbaI fragment, 
and two primers (3568 TTTTCAATGCAGGAGATGTC and 3569 
TGGTTTAGATGGAAGGATAG) that amplify a 229-bp STS were 
designed. 
FTl was isolated from a 49,XXXXY human genomic library and 
extends 8.8 kb 3’ of the human dystrophin gene polyadenylation addi- 
tion site (Chamberlain, unpublished). This portion of FTl was sub- 
cloned, and a pair of 20-bp primers were designed for use in PCR 
(primers 3328 CAATCTAACTGCAAGGAAGG and 3329 TATG- 
GAGTGAAGAACCTCTG). Th ese primers amplify a 283.bp STS, 
DXS726. 
PCR. PCR was carried out in 50 ~1 containing 10 mM Tris-HCl, 
pH 8.3, 50 mM KCl, 1.5 mM MgCI,, 0.001% gelatin, 2 pM of each 
primer, 200 KM each dNTP, 1.4 units of Taq polymerase, and 200 ng of 
genomic DNA. Reactions were covered with a 50-).d mineral oil over- 
lay. Samples were denatured at 95”C, and the enzyme was added at 
94°C and subjected to 25-35 cycles: 94°C 1 min, 50-55°C 1 min, and 
72°C 1 min, with a final 7 min at ‘72°C. The optimum annealing tem- 
perature is 50°C for primers 91-92 and 91-93 (YHX39) and primers 
3568 and 3569 (QST59) and 55°C for primers 3328 and 3329 (FTl). 
Multiplex reactions with all three sets of primers used 50°C. Blank 
(no DNA), positive control (normal human DNA), and negative con- 
trol (patient with a large Xp chromosome deletion) were included with 
each set of reactions. 
RESULTS 
Eighteen patients were characterized, and the results 
are shown in Fig. 1. The YHX39R primer pair amplified 
a 98-bp fragment, DXS727, which mapped the same as 
YHX39L by Southern blot in the patients (Fig. 1). The 
PCR results are shown in Fig. 2. The interval between 
C7 (DXS28) and YHX39R (DXS727) contained the te- 
lomeric deletion breakpoints of several patients, includ- 
ing MC, CC, TJ, MK1753, CM, IY, and YB. 
The presence of the DXS319 locus in the patients was 
determined by Southern hybridization with the probe 
pQST59M4(b) (Fig. 1). The QST59 (DXS319) primers 
amplified a 229-bp STS, and the PCR results are shown 
in Fig. 2. The QST59 STS defined a difference in the 
telomeric deletion breakpoints between patients TM 
and LB108: the telomeric deletion breakpoint for both 
patients was centromeric of YHX39 (DXS727), but only 
the telomeric deletion breakpoint for TM was centro- 
merit of QST59, presumably between DXS319 and the 
centromeric extent of AHC. 
FTl was sequenced, and primers that amplified a 283- 
bp STS (DXS726) were designed. The PCR results are 
shown in Fig. 2. 
To improve the diagnostic efficiency for diagnosis of 
patients with deletions involving this region, the three 
sets of PCR primers were combined into one multiplex 
reaction (Fig. 2). The results were identical to those seen 
in the uniplex reactions (data not shown). 
DISCUSSION 
Patients with deletions who have AHC, but not GKD 
or DMD, have been described (Yates et al., 1987; and 
DW this paper). These patients have also had develop- 
mental delay, in contrast to those with isolated AHC and 
no detectable deletions (TP,SF) who are developmen- 
tally normal and presumably have point or other small 
mutations. Patients with GKD and DMD who do not 
have AHC (Davies et al., 1988) and patients who have 
AHC and GKD but not DMD (Marlhens et al., 1987, 
Franke et al., 1987; and RR this paper) have been de- 
scribed. Analyses of DNA from these patients with Xp21 
contiguous gene syndromes have allowed the loci to be 
ordered (Xpter-ten): AHC, GK, and DMD (reviewed in 
McCabe, 1989). 

















FIG. 1. Summary of patient phenotypes and molecular genetic results. n , Presence of phenotypic features and absence of hybridization or 
amplification of probe (whichever applies). Q, Absence of phenotypic features and hybridization or amplification of probe (whichever applies). 
, A partial or a junction fragment. n and 0, Probes not tested and presumed deleted or present, respectively. The genomic probes (Towbin et 
al., 1989; McCabe et al., 1989; Francke et al.. 1987) and the DMD cDNA probes (McCabe et al., 1989) have been described previously. 
Three markers were localized in Xp21 distal to DMD, 
between DXS28 (C7) and DMD. The PCR results for 
these markers, YHX39, QST59, and FTl, confirm the 
mapping results obtained by Southern blotting. Analysis 
of DNA from patients mapped these probes (Fig. 3) with 
deletion breakpoints in each of these intervals: DXS28 
(C7) to YHX39, YHX39 to QST59, QST59 to AHC, and 
GK to FTl. Therefore, the genes for AHC and GK are 
flanked by the markers QST59 and FTl. YHX39 and 
QST59 are located between DXS28 (C7) and AHC, 
with YHX39 telomeric to QST59. FTl is between GK 
and DMD. 
One other probe has been mapped to the region be- 
tween DXS28 (C7) and DMD. This probe, JC-1, was 
cloned from the junction fragment of a patient with 
FIG. 2. Results of multiplex PCR amplification of patient DNAs 
using primers 91-92,91-93,3568,3569,3328, and 3329. The top band 
is FTl (283 bp), the middle band is QST59 (229 bp), and the bottom 
band is YHX39R (98 bp). 
DMD and GK, but not AHC (Love et al., 1990). JC-1 
maps to the region between the centromeric extent of 
the AHC and the centromeric extent of the GK genes 
(Love et al., 1990). The patient deletion breakpoints and 
the new probes (YHX39, QST59, and FTl) can be used 
as additional landmarks to expand the map in the region 
(Fig. 3). The orientation of YHX39R and YHX39L is 
determined by YAC mapping data (Worley et al., in prep- 
aration). When a complete YAC contig is developed for 
this region, all of the patient deletion breakpoints will be 
separated unless there is some feature of the DNA that 
encourages chromosome rearrangement. 
The patient deletion breakpoints define intervals that 
indicate more precisely the location of the genes in the 
region (Fig. 3). For instance, patient TM has a deletion 
that includes or interrupts the AHC gene and extends 
toward the centromere. DW has a deletion that includes 
or interrupts the AHC gene and extends toward the telo- 
mere, but does not interrupt the GK gene. Therefore, 
some or all of the interval between these two break- 
points must be within the AHC gene. Likewise, the in- 
terval between the DW centromeric deletion breakpoint 
(or the probe JC-1) and the YB and RR centromeric 
deletion breakpoints contains all or part of the GK gene. 
The patient information and the new markers are im- 
portant in terms of the diagnostic abilities in the region. 
The three new STSs have been combined into a multi- 
plex PCR reaction for DNA diagnosis. Several patients 
have had phenotypes suggesting the extension of dele- 
tions in a telomeric direction beyond DMD, but previ- 
ously available markers were unable to provide molecu- 
lar genetic evidence to support this. The markers re- 
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FIG. 3. Map of the region in Xp21 between C7 (DXS28) and FTl (no scale). The upper figures are maps of the patients’ deletions. n , Parts 
of the chromosome that are present; . ., deleted regions; and q , uncertainty in the location of the deletion breakpoints. (Bottom) Filled bars 
indicate the approximate locations of the genes for AHC (mm), GK ( and DMD (m), and open bars (0) represent the locations of various 
probes. The probe JC-1 (McCabe, 1989) has not been mapped in these patients. JC-1 may be located anywhere between the centromeric extent 
of the AHC gene and the centromeric extent of the GK gene as shown. 
ported here provide that evidence for patients MC, CC, 
TJ, MK1753, CM, IY, LB108, and TM. In addition, one 
patient, YB, with AGK (AHC, GKD) whose DNA had 
not shown a deletion with any previous probes, was 
shown to have a deletion by these markers. 
In conclusion, we have characterized three probes 
(YHX39, QST59, and FTl) and their corresponding 
STSs that map between DXS28 (C7) and DMD as 
shown. This study identified a new marker (QST59), 
which is the closest flanking marker to AHC. This has 
enabled better definition of the breakpoint for patient 
LB108, which flanks and significantly narrows the in- 
terval in which the AHC gene is located. The fact that 
both QST59 and YHX39 identify a previously undetect- 
able deletion in the patient YB confirms that QST59 is 
significantly closer to AHC than previously available 
probes. This indicates the value of these new markers, 
both for the diagnosis of AGD and for the cloning of the 
AHC and GK genes. 
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